Sensor of molecular imbalance in metabolic disorder: Determination of molecular behavior wired in disease utilizing metabolomics

Abstract

Metabolic disorders are known as one of the largest obesity epidemics and associated with health-related problems such as cardiovascular disease, diabetes, hypertension and hyperlipidemias in the US. Obesity related to an imbalance of metabolism from environmental stressors impacting metabolic rate, reflects the multi-dimensional molecular network. Obesity is also associated with the genetic predisposition of a build-up of adipose tissue dynamics, which is unable to properly undergo lipolysis and breakdown at the tissue level, or it can be a hormonal issue, where the patient is producing too much ghrelin or diminishing supply of leptin. Omics, a detection platform for macromolecules (i.e., DNA, RNA, and protein level), can be developed for use in many different types of illnesses based on the pathophysiology behind the ailment or disease, including obesity. Personalized care focused on molecule assessment can help decrease the need for synthetic insulin, increase the body’s own ability to use it’s already producing pancreatic beta cells of insulin, and decrease the likelihood of other comorbidities from progressing by adapting part of Omics metabolomics. Metabolomics is more advantageous than determining the pathologic structure of molecular behavior in ghrelin and leptin. In the future, metabolomics has strong potential to be considered as an alternative preventive tool to fight against obesity, hyperlipidemia, or secondary health complications, including cardiovascular and cancer mortality.